In the BEACON CRC study, which was conducted in a total of 221 centers in 28 countries (111 of which were centers in Europe), evaluation of the procedures used for BRAF status determination from 510 samples revealed the following picture: in 48.8% of the analyses, single gene detection was still used for BRAF testing; protein-based methods (immunohistology) were used in 0.7% of the analyses. This evidence concerns the gene BRAF and colorectal carcinoma.